A new paradigm for TB drug development is needed—one that focuses on developing not just drugs but entire drug regimens.
The Critical Path to TB Drug Regimens (CPTR) works to tackle the challenges facing TB drug development. This includes gaining support for a paradigm of drug development that enables promising combinations of drugs to be tested and developed together to create entirely new multi-drug treatments. This approach is expected to reduce the time it takes to develop an innovative regimen from decades to years. CPTR is made possible by unprecedented collaboration among pharma companies and strong commitments from public and private partners around the world. More >
STAND trial will test the first regimen designed to significantly shorten and simplify the treatment of drug-sensitive and drug-resistant TB SEATTLE (April 23, 2014)—Based on positive results from earlier clinical studies, TB Alliance is advancing the first-ever drug regimen designed to treat both drug-sensitive and some forms of multi-drug resistant tuberculosis (TB) to a global
Multi-year grant brings together non-profits, government, academia and the pharmaceutical industry to study pressing public health challenge TUCSON, Ariz., Feb. 4, 2014 /PRNewswire-USNewswire/ — The Critical Path Institute, an independent, non-profit that catalyzes innovative ideas that accelerate the speed of drug and medical product development, today announced it has received a three-year grant from the
These stories link to the WHO's Working Group on New TB Drugs